Overview
INVA market data
Price History
INVA price chart
Valuation & Profitability
- P/E (TTM)
- 4.21 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $3.20 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.39 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 81.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $16.52 – $25.15 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.5B · P/B 1.27 · P/S 3.42.
Company News
Cantor Fitzgerald Maintains Overweight on Innoviva, Lowers Price Target to $34Benzinga · Aug 7, 2026, 12:36 PM
Innoviva Q2 EPS $(1.14) Misses $0.40 Estimate, Sales $119.600M Beat $110.985M EstimateBenzinga · Aug 5, 2026, 8:43 PM
8-K filing — Innoviva, Inc. (INVA)SEC EDGAR · Aug 5, 2026, 8:19 PM
Nortiva Bio Launches Clinical-Stage Biopharmaceutical Company To Develop Long-Acting Oral MedicinesBenzinga · Jun 18, 2026, 12:15 PM
Innoviva Specialty Therapeutics Inks Agreement With Dr. Reddy's Laboratories To Develop, Commercialize XACDURO To Treat Bacterial PneumoniaBenzinga · Jun 16, 2026, 12:10 PM
HC Wainwright & Co. Reiterates Buy on Innoviva, Maintains $46 Price TargetBenzinga · Jun 1, 2026, 10:58 AM
BTIG Reiterates Buy on Innoviva, Maintains $42 Price TargetBenzinga · May 26, 2026, 11:08 AM